查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1893604

全球自体基质诱导软骨形成（AMIC）市场

Autologous Matrix-Induced Chondrogenesis (AMIC)
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 214 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年，自体基质诱导软骨形成 (AMIC) 的全球市场规模将达到 3.074 亿美元。

据估计，2024年全球自体基质诱导软骨形成（AMIC）市场规模为1.944亿美元，预计到2030年将达到3.074亿美元，在分析期（2024-2030年）内复合年增长率（CAGR）为7.9%。本报告分析的细分市场之一－胶原蛋白材料，预计在分析期间结束时将以7.6%的复合年增长率成长，达到1.756亿美元。透明质酸材料细分市场预计在分析期间将以7.1%的复合年增长率成长。

美国市场规模估计为5,650万美元，而中国市场预计将以10.0%的复合年增长率成长。

据估计，2024年美国自体基质诱导软骨形成（AMIC）市场规模将达5,650万美元。作为世界第二大经济体，中国预计到2030年市场规模将达到2,610万美元，在2024年至2030年的分析期间内，复合年增长率（CAGR）为10.0%。其他值得关注的区域市场分析包括日本和加拿大，预计在分析期间内，两国的复合年增长率分别为6.3%和7.2%。在欧洲，德国的复合年增长率预计约为8.1%。

全球自体组织诱导软骨形成（AMIC）市场－主要市场趋势与驱动因素概述

自体基质诱导软骨形成术（AMIC）是一种用于治疗关节软骨缺损的创新外科技术。此手术结合了微骨折术和生物相容性胶原蛋白膜的应用。微骨折术透过在软骨下骨上製造微小孔洞来刺激血液流动和细胞迁移。这种胶原蛋白膜作为支架，支持间质干细胞生长分化为软骨细胞，即产生软骨的细胞。 AMIC主要用于膝关节，但也可用于其他关节，例如髋关节、踝关节和肩关节。该技术旨在修復软骨损伤、减轻疼痛并改善关节功能，为传统的软骨修復方法（例如自体软骨细胞移植术（ACI））提供了创伤较小的替代方案。

AMIC手术首先透过关节镜或微创开放性手术进入软骨缺损部位。移除受损软骨后，在下方的骨头上製造微骨折，释放富含干细胞的骨髓组织。然后，将通常来自猪或牛组织的胶原蛋白膜覆盖在微骨折部位，并用纤维蛋白黏合剂或缝线固定。该膜不仅起到保护新生软骨的物理屏障作用，还能为干细胞的增生和分化提供最佳环境。随着时间的推移，这些细胞会生成新的软骨组织，并与现有软骨整合，从而促进关节的长期健康。与创伤更大的手术相比，AMIC的微创特性使其恢復时间更短，术后不适感也更轻。

自体基质诱导软骨形成术（AMIC）市场的成长受多种因素驱动，包括医疗技术的进步、关节损伤发病率的上升以及对有效软骨修復方案的需求。其中，运动伤害和骨关节炎发病率的不断攀升尤为重要，促使人们寻求创新治疗方法来恢復关节功能并缓解疼痛。生物材料和外科技术的进步也推动了AMIC的广泛应用，因为这些改进提高了手术的有效性和可靠性。此外，老年人口的成长（他们面临更高的关节退化风险）也推动了对软骨修復疗法的需求。微创手术技术的普及也促进了市场成长，因为患者越来越倾向于选择恢復时间较短、风险较低的手术方式。各地监管机构的核准和优惠的报销政策也推动了AMIC的普及。这些因素共同推动了AMIC市场的扩张和创新，确保其持续发展并在临床环境中广泛应用。

部分：

材料（胶原蛋白、透明质酸、聚乙二醇（PEG）、聚乳酸-羟基乙酸共聚物（PGLA）及其他材料）

受访公司范例

  • Anika Therapeutics, Inc.
  • Arthro Kinetics Biotechnology GmbH
  • B. Braun Melsungen
  • CONMED Corporation
  • Geistlich Pharma AG
  • JRI Orthopaedics Ltd.
  • Matricel GmbH
  • Vericel Corporation
  • Zimmer Biomet Holdings, Inc.

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，改变您分析市场和竞争情报的方式。

Market Glass, Inc. 并没有采用查询LLM 或产业专用的SLM 的典型方法，而是建立了一个由世界各地领域专家精心策划的内容库，其中包括视频转录、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

在最新发布的报告中，Market Glass, Inc. 将关税对地理市场的影响纳入考量，并根据企业总部所在地、製造地以及进出口（成品和OEM产品）预测竞争格局的变化。这种复杂多变的市场格局将对竞争对手产生诸多影响，包括销货成本增加、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 拉丁美洲
  • 世界其他地区

第四章 竞赛

简介目录
Product Code: MCP10423

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market to Reach US$307.4 Million by 2030

The global market for Autologous Matrix-Induced Chondrogenesis (AMIC) estimated at US$194.4 Million in the year 2024, is expected to reach US$307.4 Million by 2030, growing at a CAGR of 7.9% over the analysis period 2024-2030. Collagen Material, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$175.6 Million by the end of the analysis period. Growth in the Hyaluronic Acid Material segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$56.5 Million While China is Forecast to Grow at 10.0% CAGR

The Autologous Matrix-Induced Chondrogenesis (AMIC) market in the U.S. is estimated at US$56.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$26.1 Million by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.3% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market - Key Trends & Drivers Summarized

Autologous Matrix-Induced Chondrogenesis (AMIC) is an innovative surgical technique developed to treat articular cartilage defects in joints. This procedure combines microfracture surgery, which involves creating small holes in the subchondral bone to stimulate blood flow and cell migration, with the application of a biocompatible collagen membrane. The membrane serves as a scaffold to support the growth and differentiation of mesenchymal stem cells into chondrocytes, which are the cells responsible for producing cartilage. AMIC is primarily used in the knee, but it can also be applied to other joints such as the hip, ankle, and shoulder. This technique aims to repair cartilage damage, reduce pain, and improve joint function, offering a less invasive alternative to traditional cartilage repair methods like autologous chondrocyte implantation (ACI).

The procedure for AMIC begins with arthroscopic or mini-open surgery to access the cartilage defect. After debriding the damaged cartilage, microfractures are created in the underlying bone to release bone marrow elements rich in stem cells. A collagen membrane, typically derived from porcine or bovine sources, is then placed over the microfractured area and secured with fibrin glue or sutures. This membrane not only provides a physical barrier to protect the newly forming cartilage but also creates an optimal environment for the stem cells to proliferate and differentiate. Over time, these cells generate new cartilage tissue that integrates with the existing cartilage, promoting long-term joint health. The minimally invasive nature of AMIC allows for quicker recovery times and less postoperative discomfort compared to more invasive procedures.

The growth in the Autologous Matrix-Induced Chondrogenesis (AMIC) market is driven by several factors, reflecting advancements in medical technology, increasing prevalence of joint injuries, and the demand for effective cartilage repair solutions. One significant driver is the rising incidence of sports injuries and osteoarthritis, which has heightened the need for innovative treatments that can restore joint function and alleviate pain. Technological advancements in biomaterials and surgical techniques have also contributed to the adoption of AMIC, as these improvements enhance the effectiveness and reliability of the procedure. Additionally, the growing aging population, which is more susceptible to joint degeneration, has led to increased demand for cartilage repair therapies. The shift towards minimally invasive surgical techniques further supports the market growth, as patients seek procedures with shorter recovery times and lower risks. Regulatory approvals and favorable reimbursement policies in various regions are also encouraging the adoption of AMIC. These factors collectively drive the expansion and innovation in the AMIC market, ensuring its continued evolution and adoption in clinical practice.

SCOPE OF STUDY:

The report analyzes the Autologous Matrix-Induced Chondrogenesis (AMIC) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Material (Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA), Other Materials)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 28 Featured) -

  • Anika Therapeutics, Inc.
  • Arthro Kinetics Biotechnology GmbH
  • B. Braun Melsungen
  • CONMED Corporation
  • Geistlich Pharma AG
  • JRI Orthopaedics Ltd.
  • Matricel GmbH
  • Vericel Corporation
  • Zimmer Biomet Holdings, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Increasing Prevalence of Joint Disorders to Fuel Growth in Autologous Matrix-Induced Chondrogenesis Market
    • Autologous Matrix-Induced Chondrogenesis (AMIC): A Prelude
    • Global Economic Update
    • Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • INFLUENCER/PRODUCT/TECHNOLOGY INSIGHTS
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • AMIC Holds Significance in Cartilage Repair Domain
    • Rise in Sports Participation and Increase in Sports-Related Injuries Augment Growth Prospects
    • Autologous Matrix-Induced Chondrogenesis (AMIC) in Ankle Repair: A Review
    • Growing Demand for Minimally-Invasive Surgeries to Propel Market Growth
    • Rise in Incidence of Osteoporosis to Benefit Market Growth
    • Cellular Therapy as Lifeblood of Clinical Routines Targeting Cartilage Regeneration
    • AMIC: Highly Effective in Management of Focal Chondral Defects of the Knee
    • Assessment of Open & Arthroscopic Approaches for AMIC to Repair Cartilage Defects
    • MACI Solutions: Promising Options in Articular Cartilage Treatment
    • Aging Population and their Vulnerability to Various Bone and Joint Related Diseases and Disorders Drive Healthy Market Growth
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Select Musculoskeletal Conditions - Percentage Breakdown by Age Group
    • Rise in Overweight Patients to Boost Prospects
    • Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025
    • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Changing Lifestyle Impacting Bone Health
    • Rising Healthcare Spending Augurs Well for the Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Autologous Matrix-Induced Chondrogenesis (AMIC) Market Analysis of Annual Sales in US$ Thousand for Years 2017 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 4: World 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2017, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Collagen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Collagen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 7: World 13-Year Perspective for Collagen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hyaluronic Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hyaluronic Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 10: World 13-Year Perspective for Hyaluronic Acid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Polyethylene Glycol (PEG) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Polyethylene Glycol (PEG) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 13: World 13-Year Perspective for Polyethylene Glycol (PEG) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Polylactic-Co-Glycolic Acid (PGLA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Polylactic-Co-Glycolic Acid (PGLA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 16: World 13-Year Perspective for Polylactic-Co-Glycolic Acid (PGLA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 19: World 13-Year Perspective for Other Materials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America and Rest of World for Years 2017, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 22: USA 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 25: Canada 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • JAPAN
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 28: Japan 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • CHINA
    • TABLE 29: China Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 31: China 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • EUROPE
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 34: Europe 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2017, 2025 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 37: Europe 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • FRANCE
    • TABLE 38: France Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 40: France 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • GERMANY
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 43: Germany 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 46: Italy 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • UNITED KINGDOM
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 49: UK 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 52: Spain 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 55: Russia 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 58: Rest of Europe 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • ASIA-PACIFIC
    • Autologous Matrix-Induced Chondrogenesis (AMIC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 61: Asia-Pacific 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • LATIN AMERICA
    • TABLE 62: Latin America Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Latin America Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 64: Latin America 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030
  • REST OF WORLD
    • TABLE 65: Rest of World Recent Past, Current & Future Analysis for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of World Historic Review for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 67: Rest of World 13-Year Perspective for Autologous Matrix-Induced Chondrogenesis (AMIC) by Material - Percentage Breakdown of Value Sales for Collagen, Hyaluronic Acid, Polyethylene Glycol (PEG), Polylactic-Co-Glycolic Acid (PGLA) and Other Materials for the Years 2017, 2025 & 2030

IV. COMPETITION